When human peripheral blood mononuclear cells (PBM) are exposed to the cytokine interleukin-2 (IL-2) in vitro, they develop a potent cytotoxic ability referred to as lymphokineactivated killer cell (LAK-cell) activity. LAK-cell activity is characterised by the ability to kill fresh tumour cells in a non-MHC-restricted manner, while leaving normal cells (e.g. lymphocytes) unaffected (Rosenberg & Lotze, 1986) . For this reason, LAK-cells have attracted much attention as potential tools in the treatment of advanced human malignant disease and have been used clinically. There have been notable successes, particularly in the case of melanoma and renal cell carcinoma; nevertheless, the general efficacy of LAK-cell therapy has not been as great as originally envisaged (Rosenberg et al., 1985; Rosenberg, 1988) .
Several cell-types appear to contribute to the development of LAK-cell activity under the influence of IL-2, particularly T-cells, natural killer (NK) cells and large granular lymphocytes (Damle et al., 1986; Kalland et al., 1987) . However, LAK-cells differ from NK-cells in being able to kill a range of targets known to be resistant to NK activity (Grimm et al., 1982) .
As a rule, LAK-cells cannot be isolated ex vivo. Although the reasons for this are unclear, it is known that the induction of human LAK-cells in vitro can be inhibited by interleukin-4 (IL-4), which is present during the developing immune response (Brookes & Rees, 1988; Gallagher et al., 1988) . Our previous report described the effect of IL-3 and IL-4 on the ability of human LAK-cells to kill the ovarian cancer cell line OWmMl. The study reported here extends these observations in a more clinical direction by increasing the range of cytokines tested and by using primary human tumour cells as targets, as a step towards examining the role of cytokines on in vivo human LAK-cell function.
LAK-cells were generated from blood donated by healthy adult volunteers selected from the laboratory staff. PBM were isolated from these samples by density centrifugation over Ficol-Hypaque (Pharmacia) Cambridge. The killing assay was conducted over a period of 18 h. This prolonged assay was deliberately chosen over the more usual 4 h chromium-release assay in an attempt to mimic in vivo conditions more closely, where LAK-cells are expected to remain active for prolonged periods. In addition, the adherent nature of the target cells allowed us to measure the remaining live cells directly with the aid of the reducable dye MTT [3-(4,5-dimethylthoazol-2-yl)-2,5-diphenyl tetrazolium bromide]. The percentage viability of the target cells was established following their exposure to the LAK-cells (Mosmann, 1983; Gallagher et al., 1988) .
Thus, target cells were exposed to LAK-cells at an effector-to-target (E:T) cell ratio of 5:1 for 18 h in 96-well, flat-bottom plates (Sterilin). It was usual for 5 x 104 target cells to be placed in each well. At the end of the assay period, LAK-cells and dead target cells were removed by gentle but thorough washing and the culture fluid replaced with complete medium containing 0.5mgml-l MTT Recombinant human cytokines were obtained from KochLight Ltd (Haverhill, UK). A range of concentrations of each material was employed, in order to straddle that required for optimal activity in the biological system normally used to characterise particular cytokines (for example, the thymocyte co-stimulator assay for IL-1), as described by the manufacturers. The concentrations reported here represent the highest tested in our experiments: IL-1, 200 units ml-1; IL-2, 200 units ml-1; IL-3, 1,000 units ml-1; IL-4, 1,000 units ml-1; IL-6, 1,000 units ml-and GM-CSF, 1,000unitsml-1. These concentrations were found to be the most effective here and in our previous study (Gallagher et al., 1988) . It should be pointed out that the units described here are meaningless in terms of their biological activity on LAK-cells, since such effects are poorly defined. The nomenclature is retained to provide a reference to the amount of material present.
We first examined the ability of the cytokines themselves to affect the growth of the tumour cells, in the absence of LAK-cells. The experimental results are shown in Table I . The target cells were exposed to the cytokines for the full 18h of the assay period, then their viability was assessed by the MTT achieved by pre-incubating the target cells with the appropriate cytokine for 6h then washing carefully before the 18 h killing period. The ability of these cytokines to affect the killing of the target cells by the LAK-cells was then investigated. A different LAK-cell donor was used for each target cell type, for reasons of availability, and the cytokines were again present for the whole of the assay period. The experimental results are shown in Table I . The cytokines fell into three clear groups. The first group (IL-1, IL-6 and GM-CSF) did not affect the ability of LAK-cells to kill tumour targets. The second group (IL-3 and IL-4) greatly reduced the observed killing. This inhibition was effectively complete in the case of IL-4 and the Ovan-2 target, but substantial reductions in killing were observed whenever IL-3 or IL-4 was present with the LAK-cells. Finally, the presence of IL-2 greatly enhanced the ability of LAK-cells to kill human tumour-cell targets. For all target cell types examined, the results obtained from the LAKcells + IL-2, LAK-cells + IL-3 and IL-4 experiments were significantly different (greater killing with IL-2, less with IL-3 and IL-4; Student's t test, P<0.05) from the appropriate 'LAK-cells alone' experiment.
Thus, it is clear from the results described here that certain cytokines are able to regulate the effector function of human LAK-cells. While the enhancing effect of IL-2 on tumour cell killing was to be expected, the ability of IL-3 and IL-4 to inhibit the ability of human LAK-cells to kill primary human tumours ex vivo suggests that cytokines encountered within the body may reduce the efficiency of LAK-cell therapy. Because of the intimate nature of the contact between cells which produce and respond to cytokines in vivo, the concept of concentration has no meaning in an in situ context. So, although our results indicate that LAK-cells are subject to cytokine-mediated control, it is not possible to extrapolate these in vitro data to serum concentrations, for example. Both IL-3 and IL-4 have been observed as being able to reduce the efficiency of human LAK-cell induction (Brookes & Rees, 1988; Gallagher et al., 1988) (although IL-4 is reported to enhance the induction of murine LAK-cells (Mule et al., 1987; Pearce et al., 1988) . It will be interesting to examine IL-1, IL-6 and GM-CSF in this respect even though they were inactive on the effector phase of LAK-cell function, as described here.
The pure nature of the cytokines used here does not guarantee that the inhibitions observed with IL-3 and IL-4 are direct effects. The heterogeneous nature of the starting PBM population and of those cell types known to contribute to the generation of LAK-cell activity does not preclude the possibility that these cytokines are (for example) initiating interactions between T-cells and NK-cells in the LAK-cell population, which result in a reduction in observed targetcell killing. Any such ability to induce cell interactions is just as relevant as potential direct inhibitory effects, when the clinical implications are considered. Although the mechanism of action of IL-3 and IL-4 is not defined in this system, IL-3 is known to inhibit strongly the development of mouse NKcells in vivo and this may be contributing to the phenomenon described here (Kalland, 1986 (Kalland, , 1987 .
The therapeutic protocols involving LAK-cells call for these cells to be introduced to the patient in the presence of large amounts of IL-2 (Rosenberg et al., 1985) . However, cytokines interact with one another to regulate the immune response and these interactions can either enhance (Schuller et al., 1987) or suppress (Hoffman, 1986) immunological function. Thus, it appears that the immunological environment within individual patients or their tumours can adversely affect the efficacy of adoptively transferred killer cells. These relationships are of particular interest when attempting to design anti-tumour protocols based around manipulations of the patient's own immune system (Guillou, 1987) and may have serious implications for the design of combined immunotherapeutic protocols which involve treatment with cytokines other than IL-2, in combination with LAK-cells.
